Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immune Responses of Anti-HCV Antibody after Direct-Acting Antiviral Therapy Associated Allograft Injury with Acute Jaundice in Patients underwent Liver Transplantation

Shu-Hsien Lin
,
Kun-Ta Wu
ORCID logo ,
Chih-Chi Wang
,
Kuang-Tzu Huang
ORCID logo ,
Li-Wen Hsu
ORCID logo ,
Hock-Liew Eng
,
King-Wah Chiu
* ORCID logo
Version 1 : Received: 29 August 2023 / Approved: 30 August 2023 / Online: 30 August 2023 (14:51:46 CEST)
Version 2 : Received: 31 October 2023 / Approved: 3 November 2023 / Online: 3 November 2023 (14:38:36 CET)

A peer-reviewed article of this Preprint also exists.

Lin, S.-H.; Wu, K.-T.; Wang, C.-C.; Huang, K.-T.; Hsu, L.-W.; Eng, H.-L.; Chiu, K.-W. Immune Responses to Anti-Hepatitis C Virus Antibodies during Pre-Liver Transplantation Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Recipients Associated with Post-Liver Transplantation Allograft Injury. Antibodies 2024, 13, 7. Lin, S.-H.; Wu, K.-T.; Wang, C.-C.; Huang, K.-T.; Hsu, L.-W.; Eng, H.-L.; Chiu, K.-W. Immune Responses to Anti-Hepatitis C Virus Antibodies during Pre-Liver Transplantation Direct-Acting Antiviral Therapy in Hepatitis C Virus-Infected Recipients Associated with Post-Liver Transplantation Allograft Injury. Antibodies 2024, 13, 7.

Abstract

Background and Aims: The impact of antibody response after direct-acting antiviral (DAA) therapy in hepatitis C virus (HCV)-infected recipients before and after liver transplantation (LT) is still undetermined. Methods: In this observational cohort study, we aimed to explore the association of changes in anti-HCV antibody titers after pre-LT DAA therapy with allograft injury, including biliary complications (BCs) and acute cellular rejection (ACR). Results: A total of 153 cases were enrolled from January 2015 to February 2021. Serum anti-HCV antibody titers were assessed before and after (day 30) LT. Among all recipients, 31/153 (20.3%) had pre-LT DAA therapy (DAA group) and 122/153 (79.7%) did not undergo pre-LT DAA therapy (DAA-naïve group). Higher incidence of post-LT BCs was observed in the DAA group (P = 0.028). Compared with the DAA-naïve group, the DAA group had a significantly higher mean level of anti-HCV titer upregulation (P = 0.0024); furthermore, among the recipients with BCs (n = 28) and ACR (n = 41), those in the DAA group exhibited significantly higher mean levels of anti-HCV antibody titer upregulation (P < 0.005). Conclusion: In conclusion, we speculated that anti-HCV antibody titer upregulation, which might have been induced by restoration of HCV-specific immune responses with pre-LT DAA therapy, were associated with post-LT allograft injury.

Keywords

acute cellular rejection; anti-HCV antibody; biliary complications; direct-acting antivirals; hepatitis C virus; liver transplantation

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.